secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001437749-24-021339
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex begins treating patients in two new lung cancer trials, continues third
-------------------------------------------------------------------------------

- Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.
- Continues treating patients in a third lung cancer clinical trial.
- Partnered with community-based oncology practices to broaden clinical study reach.
- Expanded preclinical programs into new indications; presented positive data at major cancer conference.
- Strengthened global IP estate for lead drug candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/0001437749-24-021339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/gnpx20240507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-021339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer